





MAY 1 0 2002

ENT AND TRADEMARK OFFICE

WWW.LSC10.COV

APPLICATION NUMBER

FILING RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/910.346

07/20/2001

Lance E. Steward

D-2885CIP

CONFIRMATION NO. 2952

COPY OF PAPERS

FORMALITIES LETTER

OC000000007758666

Frank J. Uxa Suite 300 4 Venture Irvine, CA 92618

> Date Mailed: 04/01/200; Response Que 6/1

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

ORIGINALLY FILED

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, cail (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

STOUT, UXA, BUYAN & MULLINS

D-2885CIP

RECEIVED MAY 1 0 2002

MAY 1 0 2002 TECH CENTER 1600/2900

STATES PATENT AND TRADEMARK OFFICE PATENT

In the application of:

Group Art Unit: 1647

STEWARD ET AL

)

Serial No. 09/910,346

Examiner: Hayes, R

Filed: July 20,2001

COPY OF PAPERS
ORIGINALLY FILED

For: LEUCINE BASED MOTIF AND

I hereby certify that this correspondence is being

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents

CLOSTRIDIAL NEUROTOXINS

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327

Arlington, VA 22202, on or bei

rlington, VA 22202, on or before:

<u>Title</u>

<u>Date</u>

RESPONSE TO EXAMINER'S COMMUNICATION MAILED April 1, 2002

Commissioner for Patents U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Dear Sir:

This is in response to the Examiner's Communication mailed April 1, 2002. The computer readable form of the sequence listing was found to be damaged by the Examiner. Please note that before the floppy disc was mailed, the disc was checked to ensure that the sequence file could be opened and read. If the problem repeats with the new and enclosed floppy disc, please call Kyle Yesland collect at 949/450-1750.

7

REQUEST FOR ENTRY OF SEQUENCE LISTING

Submitted herewith is a "Sequence Listing" which complies with the requirements of 37 CFR 1.821-1.825, for the above-identified application, in computer readable form (CRF) and paper form. The contents of the paper and computer readable copies are the same and include no new matter.

Please enter the attached "Sequence Listing."

Respectfully submitted,

Frank J. Uxa

Attorney for Applicant

Reg. No. 25,612

4 Venture, Suite 300

Irvine, CA 92618

949/450-1750

Facsimilie - 949/450-1764